{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:12Z","timestamp":1791456672517,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05559-3","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:36:21Z","timestamp":1791448581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current perspectives and future horizons in predicting response to nutrition therapy in children with Crohn\u2019s disease \u2013 a narrative review"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-2197","authenticated-orcid":false,"given":"Paulina","family":"Krawiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"5559_CR1","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.3748\/wjg.v24.i25.2741","volume":"24","author":"J S\u00fdkora","year":"2018","unstructured":"S\u00fdkora, J. et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J. Gastroenterol. 24, 2741\u20132763 (2018).","journal-title":"World J. Gastroenterol."},{"key":"5559_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.gtc.2023.05.001","volume":"52","author":"R Khan","year":"2023","unstructured":"Khan, R., Kuenzig, M. E. & Benchimol, E. I. Epidemiology of pediatric inflammatory bowel disease. Gastroenterol. Clin. North Am. 52, 483\u2013496 (2023).","journal-title":"Gastroenterol. Clin. North Am."},{"key":"5559_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig, M. E. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 162, 1147\u20131159.e1144 (2022).","journal-title":"Gastroenterology"},{"key":"5559_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ibd\/izae093","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Global epidemiology and geographic variations of pediatric-onset inflammatory bowel disease: a comprehensive analysis of the global burden of disease study 1990 to 2019. Inflamm. Bowel Dis. 31, 376\u2013385 (2025).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs, L. et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature 642, 458\u2013466 (2025).","journal-title":"Nature"},{"key":"5559_CR6","doi-asserted-by":"crossref","unstructured":"Yue, C., Zhou, Z., Fang, L., Huang, R. & Chen, Y. The shifting burden of early-onset inflammatory bowel disease: a global analysis. Pediatr. Res. 1\u201313 (2026).","DOI":"10.1038\/s41390-026-05226-7"},{"key":"5559_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ueg2.12319","volume":"10","author":"N Singh","year":"2022","unstructured":"Singh, N. & Bernstein, C. N. Environmental risk factors for inflammatory bowel disease. United. Eur. Gastroenterol. J. 10, 1047\u20131053 (2022).","journal-title":"United. Eur. Gastroenterol. J."},{"key":"5559_CR8","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/jcag\/gwy056","volume":"2","author":"MW Carroll","year":"2019","unstructured":"Carroll, M. W. et al. The impact of inflammatory bowel disease in Canada 2018: children and adolescents with IBD. J. Can. Assoc. Gastroenterol. 2, S49\u2013S67 (2019).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"5559_CR9","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1093\/jcag\/gwad016","volume":"6","author":"W El-Matary","year":"2023","unstructured":"El-Matary, W. et al. The 2023 impact of inflammatory bowel disease in Canada: special populations-children and adolescents with IBD. J. Can. Assoc. Gastroenterol. 6, S35\u2013S44 (2023).","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"5559_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ygh2.368","volume":"1","author":"M Malham","year":"2019","unstructured":"Malham, M. et al. Paediatric onset inflammatory bowel disease is a distinct and aggressive phenotype\u2014a comparative population-based study. GastroHep 1, 266\u2013273 (2019).","journal-title":"GastroHep"},{"key":"5559_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cgh.2019.07.022","volume":"18","author":"GR Lichtenstein","year":"2020","unstructured":"Lichtenstein, G. R. et al. Lifetime economic burden of Crohn\u2019s disease and ulcerative colitis by age at diagnosis. Clin. Gastroenterol. Hepatol. 18, 889\u2013897.e810 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"5559_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.dld.2023.04.017","volume":"56","author":"M Fumery","year":"2024","unstructured":"Fumery, M. et al. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: a population-based study. Dig. Liver Dis. 56, 21\u201328 (2024).","journal-title":"Dig. Liver Dis."},{"key":"5559_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.crohns.2012.03.006","volume":"7","author":"A Assa","year":"2013","unstructured":"Assa, A. et al. Long-term outcome of tumor necrosis factor alpha antagonist\u2019s treatment in pediatric Crohn\u2019s disease. J. Crohns Colitis 7, 369\u2013376 (2013).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/ibd\/izad301","volume":"30","author":"O Atia","year":"2024","unstructured":"Atia, O. et al. Durability of adalimumab and infliximab in children with Crohn\u2019s disease: a nationwide comparison from the epi-iirn cohort. Inflamm. Bowel Dis. 30, 2097\u20132104 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR15","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/ibd\/izae226","volume":"30","author":"JS Hyams","year":"2024","unstructured":"Hyams, J. S., Winter, H. S., Mulberg, A. E. & Zuckerman, E. An open letter to the Food and Drug Administration and pharmaceutical industry concerning drug approval for children with inflammatory bowel disease. Inflamm. Bowel Dis. 30, 2523\u20132525 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1097\/MIB.0b013e3182802acc","volume":"19","author":"A Levine","year":"2013","unstructured":"Levine, A. & Wine, E. Effects of enteral nutrition on Crohn\u2019s disease: clues to the impact of diet on disease pathogenesis. Inflamm. Bowel Dis. 19, 1322\u20131329 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/apt.17109","volume":"56","author":"MH Sohouli","year":"2022","unstructured":"Sohouli, M. H. et al. Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn\u2019s disease. Aliment Pharm. Ther. 56, 384\u2013395 (2022).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR18","doi-asserted-by":"crossref","unstructured":"Jatkowska, A. et al. Partial enteral nutrition in the management of Crohn\u2019s disease: a systematic review and meta-analysis. J. Crohns Colitis 19, jjae177 (2024).","DOI":"10.1093\/ecco-jcc\/jjae177"},{"key":"5559_CR19","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/ibd\/izad255","volume":"30","author":"R Sigall Boneh","year":"2024","unstructured":"Sigall Boneh, R. et al. The Crohn\u2019s disease exclusion diet: a comprehensive review of evidence, implementation strategies, practical guidance, and future directions. Inflamm. Bowel Dis. 30, 1888\u20131902 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR20","doi-asserted-by":"crossref","unstructured":"Correia, I., Oliveira, P. A., Antunes, M. L., Raimundo, M. D. G. & Moreira, A. C. Is there evidence of Crohn\u2019s disease exclusion diet (Cded) in remission of active disease in children and adults? A systematic review. Nutrients 16, 987 (2024).","DOI":"10.3390\/nu16070987"},{"key":"5559_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/apt.14253","volume":"46","author":"A Swaminath","year":"2017","unstructured":"Swaminath, A., Feathers, A., Ananthakrishnan, A. N., Falzon, L. & Li Ferry, S. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn\u2019s disease. Aliment Pharm. Ther. 46, 645\u2013656 (2017).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","volume":"9","author":"N Chanchlani","year":"2024","unstructured":"Chanchlani, N. et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre pants cohort study. Lancet Gastroenterol. Hepatol. 9, 521\u2013538 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"5559_CR23","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma, M. M. E. et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur. J. Pediatrics 179, 1935\u20131944 (2020).","journal-title":"Eur. J. Pediatrics"},{"key":"5559_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","volume":"33","author":"CI De Bie","year":"2011","unstructured":"De Bie, C. I. et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn\u2019s disease is limited. Aliment Pharm. Ther. 33, 243\u2013250 (2011).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/MPG.0000000000001742","volume":"66","author":"R Bolia","year":"2018","unstructured":"Bolia, R. et al. Secondary loss of response to infliximab in pediatric Crohn disease: Does it matter how and when we start? J. Pediatr. Gastroenterol. Nutr. 66, 637\u2013640 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MPG.0000000000001672","volume":"66","author":"JC deBruyn","year":"2018","unstructured":"deBruyn, J. C. et al. Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience. J. Pediatr. Gastroenterol. Nutr. 66, 268\u2013273 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/MPG.0000000000000533","volume":"59","author":"JR Kelsen","year":"2014","unstructured":"Kelsen, J. R. et al. Infliximab therapy in pediatric patients 7 years of age and younger. J. Pediatr. Gastroenterol. Nutr. 59, 758\u2013762 (2014).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR28","doi-asserted-by":"crossref","unstructured":"Gaur, N., Dharwadkar, R. & Thomas, J. in Deep Learning for Targeted Treatments 171\u2013197 (Wiley Online Library, 2022).","DOI":"10.1002\/9781119857983.ch6"},{"key":"5559_CR29","doi-asserted-by":"crossref","unstructured":"Stefanicka-Wojtas, D. & Kurpas, D. Personalised medicine-implementation to the healthcare system in Europe (Focus Group Discussions). J. Pers. Med. 13, 380 (2023).","DOI":"10.3390\/jpm13030380"},{"key":"5559_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.jval.2022.01.006","volume":"25","author":"H Vellekoop","year":"2022","unstructured":"Vellekoop, H. et al. The net benefit of personalized medicine: a systematic literature review and regression analysis. Value Health 25, 1428\u20131438 (2022).","journal-title":"Value Health"},{"key":"5559_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41591-026-04309-6","volume":"32","author":"DE Coral","year":"2026","unstructured":"Coral, D. E. et al. Five tenets for advancing evidence-based precision medicine. Nat. Med. 32, 1211\u20131222 (2026).","journal-title":"Nat. Med."},{"key":"5559_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert, J. P. & Chaparro, M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J. Crohns Colitis 14, 694\u2013709 (2020).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jpn3.12096","volume":"78","author":"K Gerasimidis","year":"2024","unstructured":"Gerasimidis, K. et al. Precision nutrition in pediatric IBD: a position paper from the ESPGHAN special interest group for basic science and translational research, the IBD porto group, and allied health professionals. J. Pediatr. Gastroenterol. Nutr. 78, 428\u2013445 (2024).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/archsurg.1973.01350200189039","volume":"107","author":"AJ Voitk","year":"1973","unstructured":"Voitk, A. J., Echave, V., Feller, J. H., Brown, R. A. & Gurd, F. N. Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? Arch. Surg. 107, 329\u2013333 (1973).","journal-title":"Arch. Surg."},{"key":"5559_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/apt.17451","volume":"57","author":"SL Melton","year":"2023","unstructured":"Melton, S. L., Taylor, K. M., Gibson, P. R. & Halmos, E. P. Review article: mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn\u2019s disease. Aliment Pharm. Ther. 57, 932\u2013947 (2023).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen, P. F. et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J. Crohns Colitis 15, 171\u2013194 (2020).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.clnu.2022.12.004","volume":"42","author":"SC Bischoff","year":"2023","unstructured":"Bischoff, S. C. et al. Espen guideline on clinical nutrition in inflammatory bowel disease. Clin. Nutr. 42, 352\u2013379 (2023).","journal-title":"Clin. Nutr."},{"key":"5559_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmele","year":"2014","unstructured":"Ruemmele, F. M. et al. Consensus guidelines of Ecco\/Espghan on the medical management of pediatric Crohn\u2019s disease. J. Crohns Colitis 8, 1179\u20131207 (2014).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR39","first-page":"Cd000542","volume":"4","author":"N Narula","year":"2018","unstructured":"Narula, N. et al. Enteral nutritional therapy for induction of remission in Crohn\u2019s disease. Cochrane Database Syst. Rev. 4, Cd000542 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"5559_CR40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/ecco-jcc\/jjw075","volume":"10","author":"Z Grover","year":"2016","unstructured":"Grover, Z., Burgess, C., Muir, R., Reilly, C. & Lewindon, P. J. Early mucosal healing with exclusive enteral nutrition is associated with improved outcomes in newly diagnosed children with luminal Crohn\u2019s disease. J. Crohns Colitis 10, 1159\u20131164 (2016).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4212\/cjhp.v72i3.2903","volume":"72","author":"S Li","year":"2019","unstructured":"Li, S., Reynaert, C., Su, A. L. & Sawh, S. Efficacy and safety of infliximab in pediatric Crohn disease: a systematic review and meta-analysis. Can. J. Hosp. Pharm. 72, 227\u2013238 (2019).","journal-title":"Can. J. Hosp. Pharm."},{"key":"5559_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3813915","volume":"2022","author":"Y Lv","year":"2022","unstructured":"Lv, Y. et al. Outcomes of pediatric patients with Crohn\u2019s disease received infliximab or exclusive enteral nutrition during induction remission. Gastroenterol. Res. Pract. 2022, 3813915 (2022).","journal-title":"Gastroenterol. Res. Pract."},{"key":"5559_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clnu.2018.01.020","volume":"38","author":"JJ Ashton","year":"2019","unstructured":"Ashton, J. J., Gavin, J. & Beattie, R. M. Exclusive enteral nutrition in Crohn\u2019s disease: evidence and practicalities. Clin. Nutr. 38, 80\u201389 (2019).","journal-title":"Clin. Nutr."},{"key":"5559_CR44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.gastro.2019.04.021","volume":"157","author":"A Levine","year":"2019","unstructured":"Levine, A. et al. Crohn\u2019s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 157, 440\u2013450.e448 (2019).","journal-title":"Gastroenterology"},{"key":"5559_CR45","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1097\/MPG.0000000000001946","volume":"67","author":"M Lawley","year":"2018","unstructured":"Lawley, M. et al. Global variation in use of enteral nutrition for pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 67, e22\u2013e29 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR46","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/MPG.0000000000002847","volume":"71","author":"P Mehta","year":"2020","unstructured":"Mehta, P., Pan, Z., Furuta, G. T., Kim, D. Y. & de Zoeten, E. F. Parent perspectives on exclusive enteral nutrition for the treatment of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 71, 744\u2013748 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/ibd\/izac215","volume":"29","author":"M Cuomo","year":"2023","unstructured":"Cuomo, M. et al. Induction of remission with exclusive enteral nutrition in children with Crohn\u2019s disease: determinants of higher adherence and response. Inflamm. Bowel Dis. 29, 1380\u20131389 (2023).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/apt.12770","volume":"39","author":"K Frivolt","year":"2014","unstructured":"Frivolt, K. et al. Repeated exclusive enteral nutrition in the treatment of paediatric Crohn\u2019s disease: predictors of efficacy and outcome. Aliment Pharm. Ther. 39, 1398\u20131407 (2014).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.clnu.2019.04.015","volume":"39","author":"I Hojsak","year":"2020","unstructured":"Hojsak, I. et al. Characteristics of polymeric formula and route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in pediatric Crohn\u2019s disease. Clin. Nutr. 39, 1108\u20131111 (2020).","journal-title":"Clin. Nutr."},{"key":"5559_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3349\/ymj.2016.57.5.1185","volume":"57","author":"HJ Kim","year":"2016","unstructured":"Kim, H. J., Kim, Y., Cho, J. M., Oh, S. H. & Kim, K. M. Therapeutic efficacy of oral enteral nutrition in pediatric Crohn\u2019s disease: a single center non-comparative retrospective study. Yonsei Med. J. 57, 1185\u20131191 (2016).","journal-title":"Yonsei Med. J."},{"key":"5559_CR51","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ajcnut.2023.12.027","volume":"119","author":"B Nichols","year":"2024","unstructured":"Nichols, B. et al. Gut metabolome and microbiota signatures predict response to treatment with exclusive enteral nutrition in a prospective study in children with active Crohn\u2019s disease. Am. J. Clin. Nutr. 119, 885\u2013895 (2024).","journal-title":"Am. J. Clin. Nutr."},{"key":"5559_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.crohns.2012.07.001","volume":"7","author":"C de Bie","year":"2013","unstructured":"de Bie, C., Kindermann, A. & Escher, J. Use of exclusive enteral nutrition in paediatric Crohn\u2019s disease in the Netherlands. J. Crohns Colitis 7, 263\u2013270 (2013).","journal-title":"J. Crohns Colitis"},{"key":"5559_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15425","volume":"50","author":"M Logan","year":"2019","unstructured":"Logan, M. et al. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. Aliment Pharm. Ther. 50, 664\u2013674 (2019).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR54","unstructured":"Moriczi, M. et al. Predictors of response to exclusive enteral nutrition in newly diagnosed Crohn\u00b4s disease in children: presence study from Seghnp. Nutrients 12, 1012 (2020)."},{"key":"5559_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.874425","volume":"10","author":"W Tang","year":"2022","unstructured":"Tang, W. et al. The SES-Cd could be a predictor of short- and long-term mucosal healing after exclusive enteral nutrition in pediatric Crohn\u2019s disease patients. Front. Pediatr. 10, 874425 (2022).","journal-title":"Front. Pediatr."},{"key":"5559_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1751-2980.13260","volume":"25","author":"WJ Tang","year":"2024","unstructured":"Tang, W. J. et al. Efficacy of exclusive enteral nutrition on the mucosal healing of different gastrointestinal segments in children with Crohn\u2019s disease. J. Dig. Dis. 25, 123\u2013132 (2024).","journal-title":"J. Dig. Dis."},{"key":"5559_CR57","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s10620-005-2864-6","volume":"50","author":"NA Afzal","year":"2005","unstructured":"Afzal, N. A. et al. Colonic Crohn\u2019s disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. 50, 1471\u20131475 (2005).","journal-title":"Dig. Dis. Sci."},{"key":"5559_CR58","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3109\/00365521.2012.703234","volume":"47","author":"B Tjellstr\u00f6m","year":"2012","unstructured":"Tjellstr\u00f6m, B. et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn\u2019s disease. Scand. J. Gastroenterol. 47, 1454\u20131459 (2012).","journal-title":"Scand. J. Gastroenterol."},{"key":"5559_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2036.2009.04067.x","volume":"30","author":"E Buchanan","year":"2009","unstructured":"Buchanan, E. et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn\u2019s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharm. Ther. 30, 501\u2013507 (2009).","journal-title":"Aliment Pharm. Ther."},{"key":"5559_CR60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/MCG.0b013e3181f39af5","volume":"45","author":"K Gerasimidis","year":"2011","unstructured":"Gerasimidis, K., Nikolaou, C. K., Edwards, C. A. & McGrogan, P. Serial fecal calprotectin changes in children with Crohn\u2019s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J. Clin. Gastroenterol. 45, 234\u2013239 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"5559_CR61","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00431-018-3228-5","volume":"177","author":"I Copova","year":"2018","unstructured":"Copova, I. et al. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease. Eur. J. Pediatr. 177, 1685\u20131693 (2018).","journal-title":"Eur. J. Pediatr."},{"key":"5559_CR62","doi-asserted-by":"crossref","unstructured":"White, B. et al. Inflammation-related proteins support diagnosis of inflammatory bowel disease and are modified by exclusive enteral nutrition in children with Crohn\u2019s disease, especially of ileal phenotype. Inflamm. Bowel Dis. 31, 733\u2013745 (2024).","DOI":"10.1093\/ibd\/izae107"},{"key":"5559_CR63","doi-asserted-by":"publisher","first-page":"120127","DOI":"10.1016\/j.bbamcr.2026.120127","volume":"1873","author":"K D\u00f6hner","year":"2026","unstructured":"D\u00f6hner, K., John, O. P. & Werfel, T. Thymic Stromal Lymphopoietin (TSLP) - pro-inflammatory cytokine and antimicrobial peptide. Biochim. Biophys. Acta Mol. Cell Res. 1873, 120127 (2026).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"5559_CR64","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang, J. T. Pathophysiology of inflammatory bowel diseases. N. Engl. J. Med. 383, 2652\u20132664 (2020).","journal-title":"N. Engl. J. Med."},{"key":"5559_CR65","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492\u2013506 (2020).","journal-title":"Cell Res."},{"key":"5559_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan, Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J. Immunol. Res. 2019, 7247238 (2019).","journal-title":"J. Immunol. Res."},{"key":"5559_CR67","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1097\/MIB.0000000000000956","volume":"22","author":"KA Dunn","year":"2016","unstructured":"Dunn, K. A. et al. Early changes in microbial community structure are associated with sustained remission after nutritional treatment of pediatric Crohn\u2019s disease. Inflamm. Bowel Dis. 22, 2853\u20132862 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-015-0073-x","volume":"3","author":"M Shafiei","year":"2015","unstructured":"Shafiei, M. et al. Biomico: a supervised Bayesian model for inference of microbial community structure. Microbiome 3, 8 (2015).","journal-title":"Microbiome"},{"key":"5559_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75306-z","volume":"10","author":"K Diederen","year":"2020","unstructured":"Diederen, K. et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn\u2019s disease. Sci. Rep. 10, 18879 (2020).","journal-title":"Sci. Rep."},{"key":"5559_CR70","doi-asserted-by":"crossref","unstructured":"Hart, L. et al. Effect of exclusive enteral nutrition and corticosteroid induction therapy on the gut microbiota of pediatric patients with inflammatory bowel disease. Nutrients 12, 1691 (2020).","DOI":"10.3390\/nu12061691"},{"key":"5559_CR71","doi-asserted-by":"crossref","unstructured":"Dijk, S. et al. Pre-diagnosis diet predicts response to exclusive enteral nutrition and correlates with microbiome in pediatric Crohn disease. Nutrients 16, 1033 (2024).","DOI":"10.3390\/nu16071033"},{"key":"5559_CR72","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/ibd\/izaa001","volume":"26","author":"CMA Jones","year":"2020","unstructured":"Jones, C. M. A. et al. Bacterial taxa and functions are predictive of sustained remission following exclusive enteral nutrition in pediatric Crohn\u2019s disease. Inflamm. Bowel Dis. 26, 1026\u20131037 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR73","doi-asserted-by":"publisher","first-page":"100948","DOI":"10.1016\/j.lanmic.2024.07.011","volume":"6","author":"J Rodriguez","year":"2025","unstructured":"Rodriguez, J. et al. State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus. Lancet Microbe 6, 100948 (2025).","journal-title":"Lancet Microbe"},{"key":"5559_CR74","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1136\/gutjnl-2017-315866","volume":"67","author":"A Levine","year":"2018","unstructured":"Levine, A., Sigall Boneh, R. & Wine, E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 67, 1726\u20131738 (2018).","journal-title":"Gut"},{"key":"5559_CR75","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1097\/MIB.0000000000000110","volume":"20","author":"R Sigall-Boneh","year":"2014","unstructured":"Sigall-Boneh, R. et al. Partial enteral nutrition with a Crohn\u2019s disease exclusion diet is effective for induction of remission in children and young adults with Crohn\u2019s disease. Inflamm. Bowel Dis. 20, 1353\u20131360 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"5559_CR76","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.cgh.2020.04.006","volume":"19","author":"R Sigall Boneh","year":"2021","unstructured":"Sigall Boneh, R. et al. Dietary therapies induce rapid response and remission in pediatric patients with active Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 19, 752\u2013759 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"5559_CR77","doi-asserted-by":"crossref","unstructured":"Sigall Boneh, R. et al. Modified Crohn\u2019s disease exclusion diet maintains remission in pediatric Crohn\u2019s disease: randomized controlled trial. Clin. Gastroenterol. Hepatol. 23, 2001\u20132011 (2024).","DOI":"10.1016\/j.cgh.2024.12.006"},{"key":"5559_CR78","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/jpn3.12283","volume":"79","author":"L Scarallo","year":"2024","unstructured":"Scarallo, L. et al. A real-life pediatric experience of crohn\u2019s disease exclusion diet at disease onset and in refractory patients. J. Pediatr. Gastroenterol. Nutr. 79, 592\u2013601 (2024).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5559_CR79","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fmed.2020.00517","volume":"7","author":"R Atreya","year":"2020","unstructured":"Atreya, R., Neurath, M. F. & Siegmund, B. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? Front. Med. 7, 517 (2020).","journal-title":"Front. Med."},{"key":"5559_CR80","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","volume":"22","author":"R Atreya","year":"2024","unstructured":"Atreya, R. & Neurath, M. F. Biomarkers for personalizing IBD therapy: the quest continues. Clin. Gastroenterol. Hepatol. 22, 1353\u20131364 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"5559_CR81","doi-asserted-by":"crossref","unstructured":"Molla, G. & Bitew, M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines 12, 2750 (2024).","DOI":"10.3390\/biomedicines12122750"},{"key":"5559_CR82","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","volume":"520","author":"NJ Schork","year":"2015","unstructured":"Schork, N. J. Personalized medicine: time for one-person trials. Nature 520, 609\u2013611 (2015).","journal-title":"Nature"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05559-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05559-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:50Z","timestamp":1791453770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05559-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":82,"alternative-id":["5559"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05559-3","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K. declares no specific conflict of interest related to this study. L.dR. in the previous 3 years has received speaker\u2019s fees (Celltrion, Takeda, Pfizer), grant (Pfizer), participated in a DSMB (Alvotech).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}